---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-097153"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:36:54.447712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease

## Summary
- GT-02287 safe and well-tolerated after 90 days; no serious adverse events.
- Transient liver enzyme increases normalized with ongoing dosing.
- Mean UPDRS Part II and III scores improved at Day 90, suggesting disease-slowing effect.
- Plasma PK consistent across 14 participants, within therapeutic range.
- DMC recommended continuation; Australian authorities approved 12-month extension.

## SEC filing metadata
- accession: 0001104659-25-097153
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/0001104659-25-097153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/tm2528094d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-097153
- JSON: https://secwatch.observer/filing/0001104659-25-097153.json
- Plain text: https://secwatch.observer/filing/0001104659-25-097153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.